holog say bye riddanc cynosur
updat forecast estim dec
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim dec
price data dec
rate updat dec
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
ceo stephen macmillan watch abl
focu structur competit advantag improv balanc
sheet judici step complimentari market
even vagari product cycl control roughli
 digit mammographi market lead way
first mammographi adopt slow
clinic data still give edg larger competitor
still opportun sell ancillari accessori
mammogram biopsi
pricey gen-prob acquisit also hold top
posit host diagnost test focus women health
run sole proprietari instrument think
done good job capit prolifer low-
midvolum lab panther equip gain
traction expand recur revenu base
howev face secular competit hurdl
recommend cervic screen interv lengthen
reduc pap smear volum forc preserv
market share hpv price also fallen
dramat seek maintain share addit
heavy-weight siemen compet
mammographi market could challeng given ge
entrench select hospit abil bundl extens
menu capit equip
materi think done good job navig
pressur center medicar medicaid servic
establish reimburs mammographi appear
lucr firm custom base bolster
adopt believ first-mov advantag
mammographi wide instal base strong trial valid
provid firm foot market pleas
success seen reorgan support
robust growth penetr key franchis europ
develop market firm footprint outsid
long soft spot see progress
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
manufactur proprietari product healthcar need
women compani oper five segment breast health
sale diagnost surgic skelet health
compani tradit focus breast health acquisit
gen-prob put greater emphasi commerci diagnost unit
state account largest portion firm revenu follow
europ asia intern market holog
headquart bedford massachusett
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
holog say bye riddanc cynosur
news particularli surpris applaud
holog decis sell cynosur medic aesthet
busi privat equiti model divestitur
cynosur off-set slightli robust
project breast health diagnost busi
midterm along cash flow realiz sinc
last updat weve rais fair valu estim
per share weve long thought holog narrow
econom moat stem mainli switch cost
intang asset breast health diagnost -- two
key product segment thu impend divest
no-moat medic aesthet doesnt hold moat
implic perspect
would difficult describ purchas cynosur
billion anyth disastr capit
alloc sinc purchas fiscal
record signific impair charg sell
cynosur million acquisit cynosur
also underscor substanti integr risk med-
tech sale rep relationship clinic practition
remain signific intang asset relationship
extrem valuabl also vulner sale rep
depart case cynosur look across
med-tech case think help acquir
intellectu properti especi proprietari clinic
data part receiv purchas
compani provid strong foundat
acquir continu sell acquir product
case cynosur there littl clinic evid
protect competitor success medic
aesthet laser remain larg driven market
sale rep relationship
pleas see medic aesthet
franchis longer occupi time attent
slightli rais fair valu estim
per share increas primarili driven
breast health
diagnost segment midterm secondarili
cash flow realiz sinc last updat factor
partial off-set impend sale legaci
cynosur busi continu think firm well
posit roll-out panther instrument
widen stream recur test revenu also
believ entri viral-load test boost
appeal assay menu aid stabil
hpv test market intern side
anticip continu expans europ slow
entri emerg market play greater role
gain surgic skelet health follow
divest cynosur fiscal project compound-annual-growth-rate
time frame
believ price pressur persist across
product forecast gross margin increas
increment firm increas recur
revenu higher-margin test servic expans
instal base mammographi equip
panther unit divest lower-margin cynosur
also help profit peripheri
believ firm sale mix capit equip
consum servic revenu translat averag
cash flow volatil warrant medium uncertainti
firm abil maintain instal base
diagnost instrument expand test
menu well quickli medic aesthet
segment return market-r growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
pioneer first fda-approv mammographi
platform continu expand instal
base unit mammographi equip
typic big-ticket purchas hospit
radiolog clinic price tag per digit
unit per instal time
retrain system reorgan work flow mean
custom littl incent switch platform
furthermor consider less expens
holog custom upgrad equip rather
switch compet system sizabl instal
base firm also reap benefit five-year servic
contract annual cost purchas
price option instal base
fall contract
addit lengthi fda approv process
sophist technolog tall barrier deter
new market entrant though gener electr
siemen receiv fda approv system
add new level competit could appli
price pressur think grow bodi clinic data
geniu system help establish superior
mind clinician three year
new competit yet seen soft
averag sell price
acquir gen-prob purchas cytyc
diagnost divis also leverag
high switch cost surround proprietari
instrument test run ad
thinprep lead share liquid-bas pap market
capabl hpv chlamydia gonorrhea trichomona
blood screen lab commit firm autom
equip streamlin oper run compani
test consolid workflow fewer platform addit
time requir train lab technician adjust work
cost built around
bull-cas scenario fair valu rise per
share assum introduct new assay lead
diagnost growth quicker-than-expect adopt
greater proport sale
segment shift toward consum accessori
effici usag salesforc project oper
margin increas basi point beyond base case
bearish scenario peg fair valu per
share assum greater competit price
pressur across busi segment hinder growth
particularli diagnost assum slowdown europ
emerg market also bake stringent
requir approv regulatori agenc
translat compound annual growth
consolid oper margin reach fiscal
believ dug narrow econom moat base
switch cost intellectu properti
surround breast health diagnost platform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
believ moat trend stabl within breast
health competit ramp ge
siemen receiv regulatori approv rival
enjoy strong brand name access greater resourc
technolog innov nevertheless uptak
platform remain solid size
compani digit instal base give us confid
maintain momentum upgrad despit new
entrant market remain competit
need maintain technolog edg equip
upgrad new product introduct appeal
within diagnost consider headwind pap
smear market seem eas diagnost oem
adjust longer recommend test interv
push annual pap smear closer everi three five
year women fortun consist
introduc expand menu test well
enhanc front-end autom capabl
overal feel firm well posit
front broaden portfolio test sexual
transmit diseas enter viral-load test hiv
hep area billion market
instrument price tag built
build meaning brand
acquisit cynosur provid sizabl
footprint aesthet market howev think
medic aesthet busi worthi moat
think busi bolster
moat cosmet laser market vulner
disrupt technolog low barrier entri rel
low switch cost littl clinic data differenti
competit product manufactur compet primarili
basi market potenti
direct-to-consum commun could
contribut moat yet see firm
demonstr kind market chop would take
get firm recent announc intent
sell cynosur privat equiti littl chang view
moat resid breast health
vitro diagnost technolog anyth think
decis sell like good strateg choic allow
focu build breast health
portfolio develop new assay diagnost
equip think better invest
manag energi rebuild medic
aesthet commerci organ steadi stream
sale rep left
think holog remain segment surgic
skelet health moat firm hysteroscop
surgic product myosur led pocket success
strong cash flow howev lower-cost altern
put pressur novasur product advers
macroeconom condit result mix skelet
result nevertheless believ breast health
diagnost segment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
first market fda-approv
mammographi platform unit state give
consider head start gener electr
siemen
control lion share liquid-
base pap market gen-prob acquisit
catapult firm number-on posit
test chlamydia gonorrhea blood screen
ogovern reimburs mammographi
appear lucr custom base
acceler system placement
owith mammographi screen guidelin flux
potenti drop-off mammogram volum could hurt
product portfolio vari wide see
littl opportun effici use salesforc
call differ specialist
odespit full pipelin best effort high
degre clinic regulatori risk surround
product regulatori path approv
expens time-consum fruitless process
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
took consider leverag billion
acquisit gen-prob deleverag
ensu year avoid pile debt
purchas cynosur septemb owe
billion long-term debt held million cash
repres net debt/adjust ebitda shi time
macmillan lead firm note prefer
oper firm substanti less leverag
balanc sheet held begin tenur
net debt/ebitda macmillan
balanc sheet typic held cash debt
set hit goal time net debt/ebitda
end fiscal
believ sale mix capit equip
consum servic revenu translat averag
cash flow volatil warrant medium uncertainti
rate sale influenc capit spend
pattern hospit clinic could advers
affect prolong econom downturn effect
macroeconom downturn could exacerb
consum forgo cosmet laser treatment
interest tighten financi belt diagnost
market particip
also
competit firm sale could suffer screen
guidelin lengthen becom lenient furthermor
signific exposur regulatori risk
particularli within secur reimburs fda
approv new product introduct also
approxim sale come intern
market currenc headwind could neg impact
top- bottom-lin perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
board director
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
award holog standard mark stewardship
stephen macmillan step ceo late
macmillan formerli serv ceo
corpor hold
year oper experi healthcar
industri overal think macmillan well suit
job follow effect tenur execut
number success direct make sound
acquisit experi benefit
oper strategi macmillan also track record
gener free cash flow manag debt holog
benefit firm deleverag balanc
sheet follow gen-prob acquisit put holog
favor posit make acquisit broaden
firm footprint
primari complaint holog high-profil
acquisit come hefti price follow
substanti goodwil write-off rack
signific record substanti write-off last
year base disclos goodwil impair
last two year along estim eventu
impair declar sale
cynosur written billion
impair associ busi note
paid billion cynosur fiscal
revalu goodwil led billion
impair charg relat third wave
gen-prob even earlier billion
relat cytyc acquisit entir string
impair reflect current manag
team recogn cumul impact
independ decis differ manag
team cost sharehold point rather see
buy back share embark anoth larg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
holog say bye riddanc cynosur
news particularli surpris applaud
holog decis sell cynosur medic aesthet
busi privat equiti model divestitur
cynosur off-set slightli robust
project breast health diagnost busi
midterm along cash flow realiz sinc
last updat weve rais fair valu estim
per share weve long thought holog narrow
econom moat stem mainli switch cost
intang asset breast health diagnost -- two
key product segment thu impend divest
no-moat medic aesthet doesnt hold moat
implic perspect
would difficult describ purchas cynosur
billion anyth disastr capit
alloc sinc purchas fiscal
record signific impair charg sell
cynosur million acquisit cynosur
also underscor substanti integr risk med-
tech sale rep relationship clinic practition
remain signific intang asset relationship
extrem valuabl also vulner sale rep
depart case cynosur look across
med-tech case think help acquir
intellectu properti especi proprietari clinic
data part receiv purchas
compani provid strong foundat
acquir continu sell acquir product
case cynosur there littl clinic evid
protect competitor success medic
aesthet laser remain larg driven market
sale rep relationship
franchis longer occupi time attent
chang fair valu estim
finish fiscal year strength
leav fair valu estim unchang see littl
materi alter estim fiscal sinc
project top bottom line well within
rang manag outlook though weve long thought
dug narrow econom moat basi
intang asset switch cost latest strateg
move serv reinforc firm moat
perspect particular like shift
breast health busi incorpor consum
product softwar upgrad go beyond sale
capit equip thank seri tuck-in acquisit
shape comprehens portfolio
mammographi biopsi expect stream on-going
innov breast health support mid-single-digit
growth seen recent unit
look forward develop introduct
artifici intellig product breast imag though
manag downplay growth expect
near term product optimist
potenti hold longer term rang clinic
studi consist suggest appli
element machin learn could significantli improv
rate accuraci mammogram especi reduc
number fals posit think strong
posit roll product given firm alreadi
leader mammographi enjoy larg instal
base also like product would tap
enhanc valu data captur mammogram
pleas see medic aesthet
final reassur manag comment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
success tuck-in acquisit strategi think
approach like help avoid larg expens
acquisit led major write-off past
includ gen-prob cynosur
constant currenc definit improv
compar last four quarter declin seem
bottom fiscal second quarter expect
unit return growth new salesforc becom
product
holog show sign strength fiscal third quarter
chang fair valu estim aug
sustain firm recent growth slight
adjust assumpt werent enough move
needl valuat remain confid
holog narrow econom moat pleas see
broad-bas strength across product line
quarter begin see firm reap
reward effort introduc increment innov
adjac technolog breast health increas
demand molecular diagnost especi assay
consid mid-tier size compar
larger competitor vitro diagnost breast
roch -- make sens expand
presenc addit complimentari product
market alreadi establish footprint
like eas fold breast imag biopsi
product exist portfolio leverag
instal base holog geniu
mammographi machin expect
acquisit super sonic imagin pair nice ad
ultrasound imag capabl compliment holog
presenc mammographi ultrasound imag often
follow step abnorm screen mammogram
use guid needl biopsi procedur
final see light end tunnel medic
aesthet busi though quarterli revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end septemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
